Geller Advisors LLC Sells 500 Shares of Edwards Lifesciences Co. (NYSE:EW)

Geller Advisors LLC lowered its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 14.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 3,046 shares of the medical research company’s stock after selling 500 shares during the quarter. Geller Advisors LLC’s holdings in Edwards Lifesciences were worth $225,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Gotham Asset Management LLC raised its holdings in shares of Edwards Lifesciences by 105.8% in the fourth quarter. Gotham Asset Management LLC now owns 16,423 shares of the medical research company’s stock worth $1,216,000 after buying an additional 8,444 shares during the period. Focus Partners Wealth increased its stake in Edwards Lifesciences by 43.9% in the fourth quarter. Focus Partners Wealth now owns 63,380 shares of the medical research company’s stock worth $5,089,000 after purchasing an additional 19,347 shares during the period. Farallon Capital Management LLC bought a new stake in shares of Edwards Lifesciences during the fourth quarter worth $222,000. Fiduciary Trust Co boosted its stake in shares of Edwards Lifesciences by 9.3% during the fourth quarter. Fiduciary Trust Co now owns 14,954 shares of the medical research company’s stock valued at $1,107,000 after purchasing an additional 1,268 shares during the period. Finally, Deutsche Bank AG grew its holdings in shares of Edwards Lifesciences by 10.4% in the fourth quarter. Deutsche Bank AG now owns 6,903,202 shares of the medical research company’s stock worth $511,044,000 after purchasing an additional 652,923 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In other news, Director Steven R. Loranger sold 5,739 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.38. Following the completion of the sale, the director now directly owns 60,372 shares in the company, valued at $4,613,628.24. The trade was a 8.68 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the company’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $67.96, for a total value of $645,620.00. Following the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,189,770.56. The trade was a 16.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 89,681 shares of company stock worth $6,492,703. 1.29% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research firms have commented on EW. StockNews.com raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Thursday. Truist Financial lowered their target price on Edwards Lifesciences from $78.00 to $75.00 and set a “hold” rating for the company in a report on Friday, April 11th. Stifel Nicolaus upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and lifted their price target for the company from $75.00 to $90.00 in a report on Thursday, January 30th. Morgan Stanley raised their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 12th. Finally, Piper Sandler upgraded shares of Edwards Lifesciences from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $73.00 to $80.00 in a report on Thursday, April 24th. One research analyst has rated the stock with a sell rating, twelve have given a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $79.45.

Edwards Lifesciences Stock Performance

NYSE EW opened at $73.82 on Friday. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $95.25. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The firm has a market capitalization of $43.40 billion, a P/E ratio of 10.59, a PEG ratio of 4.82 and a beta of 1.12. The stock has a 50-day simple moving average of $71.48 and a two-hundred day simple moving average of $71.50.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.60 by $0.04. The company had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Edwards Lifesciences’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.66 earnings per share. On average, equities analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.